

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M. 7716 - PFIZER / GSK MENACWY BUSINESS

SECTION 1.2

Description of the concentration

On 17 August 2015, Pfizer Ireland Pharmaceuticals ("**Pfizer**") submitted to the European Commission a notification of a proposed acquisition of sole control by Pfizer over the Nimenrix and Mencevax Meningococcal ACWY Vaccines, part of GlaxoSmithKline Biologicals S.A. ("**GSK**") meningococcal vaccines business. This acquisition is being entered into pursuant to the Commitments imposed by the European Commission in its decision of 28 January 2015 in Case M.7276 (GLAXOSMITHKLINE/NOVARTIS VACCINES BUSINESS (EXCL. INFLUENZA)/ NOVARTIS CONSUMER HEALTH BUSINESS) as a condition for clearance.

Pfizer is a wholly owned indirect subsidiary of Pfizer Inc. Pfizer has a manufacturing presence in Active Pharmaceutical Ingredients, Solid Dose Pharmaceuticals, Sterile Injectables, Nutritionals, Vaccines and Biopharmaceuticals, commercial Human Prescription, Animal Health and Consumer Health products businesses.

GSK, a subsidiary of GlaxoSmithKline plc researches, develops, manufactures, and supplies vaccines. Its vaccination products are used to tackle various diseases such as rabies, diphtheria, tetanus, and yellow fever as well as polio, measles, mumps, rubella, and Hepatitis B.